Nona Biosciences and Kodiak Sciences Collaborate to Develop Novel Antibodies for Ophthalmic Diseases
Nona Biosciences has announced a strategic partnership with Kodiak Sciences Inc. to advance the development of innovative multi-target antibodies for treating ophthalmic diseases. This collaboration leverages Nona’s proprietary Harbour Mice platform, a cutting-edge technology designed to generate fully human antibodies, streamlining the discovery and development process for next-generation therapies.
Harbour Mice Technology: A Game-Changer in Antibody Development
The Harbour Mice platform offers two powerful formats for antibody production:
• H2L2 Format: Produces fully human monoclonal antibodies with two heavy and two light chains, mimicking the traditional IgG structure.
• HCAb Format: Generates advanced heavy chain-only antibodies that are approximately half the size of conventional IgGs.
The HCAb format provides unique advantages for developing next-generation antibody therapies, including improved functionality and reduced need for engineering or humanization.
Partnership Scope
Under the agreement, Kodiak Sciences will gain access to both the H2L2 and HCAb Harbour Mice platforms for multiple therapeutic antibody discovery programs aimed at addressing complex ophthalmic conditions.
Leadership Perspectives
Nona Biosciences: Driving Innovation in Ophthalmic Antibodies
Dr. Jingsong Wang, Chairman of Nona Biosciences, expressed enthusiasm about the collaboration:
“We are excited to partner with Kodiak Sciences to develop novel therapeutic antibodies for ophthalmic diseases. This agreement underscores the strength of our Harbour Mice technology and our commitment to advancing next-generation therapies. With Nona’s expertise and cutting-edge platforms, we look forward to helping Kodiak accelerate its antibody development efforts and deliver innovative treatments to patients.”
Kodiak Sciences: Tackling Complex Retinal Diseases
Dr. Victor Perlroth, Chairman and CEO of Kodiak Sciences, highlighted the critical need for multi-target therapies:
“Retinal diseases are challenging due to their complex causes, so developing effective treatments requires targeting multiple pathways simultaneously. Our partnership with Nona Biosciences, leveraging their advanced Harbour Mice platforms and expertise in antibody discovery, will be key to accelerating our work in creating next-generation biotherapeutics. Together, we are poised to bring breakthrough treatments to patients who need them the most.”
Advancing Ophthalmic Therapeutics
This collaboration between Nona Biosciences and Kodiak Sciences represents a significant step forward in addressing the unmet needs of patients with retinal and other ophthalmic diseases. By combining cutting-edge technology with deep expertise in antibody discovery, the partnership aims to deliver groundbreaking therapies that transform the landscape of ophthalmic care.
